Atezolizumab for adjuvant treatment of high-risk locally advanced squamous cell head and neck cancer [ID4052]Status:Awaiting developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Leukocyte interleukin in combination for neoadjuvant treatment of resectable locally advanced squamous cell head and neck cancer TS ID 10203Status:Awaiting developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Pembrolizumab with lenvatinib for untreated PD-L1 positive recurrent or metastatic squamous cell head and neck cancer [ID5118]Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Toripalimab with chemotherapy for untreated recurrent or metastatic nasopharyngeal cancer [ID6406]Status:Awaiting developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Xevinapant with platinum-based chemotherapy and radiotherapy for untreated locally advanced squamous cell head and neck cancer [ID6199]Status:Awaiting developmentProgramme:Technology appraisal guidanceExpected publication date: TBC